EUCTR2020-003404-14-BG进行中（未招募）1 期
A comparative study to assess a fixed-dose combination of Budesonide-Salmeterol versus Serevent® Diskus® 50 µg + Pulmicort® Turbuhaler® 100 µg co-administrated in asthmatic children: single dose, cross-over, randomized, 3-treatment
aboratoires SMB S.A.0 个研究点目标入组 14 人开始时间: 2020年12月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or premenarchal female subjects aged between 6 and 11 years, inclusive.
- •2.Caucasian.
- •3.Asthma diagnosed according to the GINA guidelines based on symptoms typical of childhood asthma, within at least 3 months prior to screening.
- •4.Subject presenting an increase in FEV1 of at least 12% of the FEV1 predicted value at reversibility test after 200 µg of salbutamol at screening visit. If the level of reversibility is not achieved at screening, 1 repeat measurement of reversibility is allowed during the screening period within seven days after Visit 1 if there is reasonable belief that the patient can achieve the expected reversibility.
- •5.Patients not weighing less than 19 kg
- •6.Body mass index (BMI) within the 5th to 95th percentile of the BMI charts/tables recommended by the world health organization (WHO) based on stature-for-age and weight-for-age and by gender. (Charts presented in appendix 18.5)
- •7.Able to comply with all study procedures, including the use of study inhalers (Vertical-Haler®, Diskus®, Turbuhaler®) and spirometer. Note: Since formal training and test for the correct handling of the DISKUS® and TURBUHALER® inhalers could not be provided the Investigator should check if the child understands the instructions provided for the inhalers use and is aware of their proper use. Willing to withhold the use of short acting ß-agonists for at least 6 hours prior to the screening visit and at least 6 hours prior to each study visit.
- •8.Written informed consent for the patient to participate in the study by the parent(s) or legal guardian(s) as applicable and if possible - a written assent by the patient.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 14
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Drug addiction or excessive use of xanthine containing beverages (5 cups of tea, coffee, cacao, cola, ice tea)
- •2.Severe, life-threatening asthma or hospitalisation for an asthma exacerbation within 3 months prior to the screening visit and hospitalisation for a related disorder (pneumothorax, bronchopneumonia etc) in the past 3 months
- •3.Evidence of any unstable or untreated clinically significant immunological, neoplastic, endocrine, haematological, hepatic, renal, gastrointestinal, neurological or psychiatric abnormality, or disease
- •4.Respiratory tract infection requiring treatment with antibiotics within 4 weeks prior to the screening visit
- •5.Any significant upper and lower respiratory infection (other than asthma) within the previous 4 weeks before screening visit
- •6.Pure seasonal asthma and/ or a history of seasonal exacerbation of asthma
- •7.Use of any of the prohibited medications as detailed in the concomitant medication section 10.9
- •8. Clinical evidence of candidiasis or other fungal airway infection at the screening visit
- •9.Participation in any other clinical trial within 3 months of the screening visit
- •10.Blood donation within 3 months before the screening visit
- •11.Presence of any other condition or illness, which, in the opinion of the investigator would interfere with optimal participation in the study
- •12Patients with any sensitivity or allergy to any of the products (including excipients) used within this clinical trial
- •13Patient known to have, or at risk of contracting, human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C or patients with positive virology laboratory tests (HBsAg, HCV Ab, HIV 1+2 Ab)
- •14Patients with diabetes mellitus
- •15Subjects previously enrolled into the current study.
- •16First-degree relative of a study investigator, or of employee of the clinical study site or of the sponsor
研究者
相似试验
已完成
4 期
Efficacy and Safety Study Tablet ( Irpo- FA®) in Pregnant WomeIron Deficiency & Folic acid Deficiency anemia.Iron deficiency anaemia, unspecified & Folate deficiency anaemia, unspecifiedD-50 & D-5IRCT201610197978N3abiqasim Industries (Pvt) Ltd.50
已完成
3 期
Safety and Efficacy Study of Fixed Dose Combination of Three Antidiabetic Drugs in Comparison to Two Antidiabetic Drugs in Patients with Type 2 DiabetesCTRI/2016/11/007439Sun Pharma Laboratories Limited301
已完成
3 期
A clinical trial to study the efficacy and safety of combination drugs of chlorthalidone, metoprolol and telmisartan in treatment of high blood pressure with stable coronary artery disease.CTRI/2016/11/007491Sun Pharma Laboratories Limited254
进行中（未招募）
1 期
Estudio de la combinación a dosis fija de comprimidos de Telmisartán 80 mg más Amlodipino 10 mg versus comprimidos sobreencapsulados de Amlodipino 10 mg como terapia de primera linea en pacientes con diabetes mellitus tipo 2 e hipertensión grado 1 ó 2: comparación de fase III, de 8 semanas, aleatorizada, a doble ciego, con doble enmascaramiento y titulación forzadaTElmisartan 80 mg plus AMlodipine 10 mg fixed-dose combination tablet STudy versus Amlodipine 10 mg over-encapsulated tablets as first line therapy inpatients with Type 2 Diabetes Mellitus and Stage I or II hypertension: a Phase III, eight week, randomised, double-blind, double-dummy, forced titration comparisoHipertensiónHypertensionMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionEUCTR2008-000874-19-ESBoehringer Ingelheim Esapaña, S.A.400
进行中（未招募）
1 期
Estudio de la combinación a dosis fija de comprimidos de Telmisartán 80 mg más Amlodipino 10 mg versus comprimidos sobreencapsulados de Amlodipino 10 mg o comprimidos de Telmisartán 80 mg como terapia de primera linea en pacientes con hipertensión grave: comparación de fase III, de 8 semanas, aleatorizada, a doble ciego, con doble enmascaramiento y titulación forzada (TEAMSTA severe HTN).TElmisartan 80 mg plus AMlodipine 10 mg fixed-dose combination tablet STudy versus Amlodipine 10 mg over encapsulated tablets or telmisartan 80 mg tablets as first line therapy in patients with severe HyperTeNsion: A Phase III, 8-week, randomised, double-blind, double-dummy, forced-titration comparison [TEAMSTA severe HTN] - TEAMSTA Severe HTEUCTR2008-000873-40-ESBoehringer Ingelheim España, S.A.760